stockrow
Saturday 7 November 2026
Export CDT’s income statement to Excel — free account
CDT Equity Inc.
- EPS
- +99.9%
- Free cash flow
- +78.9%
Quarter to June 2026, against a year earlier
1.31
0.46
+54.12%
Follow CDT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 0 | (5) | (1) | (18) | (39) | (37) | +871.7% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | — | — | 0 | (5) | (1) | (18) | (39) | (37) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | 0.00 | (0.13) | (599,114.00) | (15,389,810.00) | (294,472.50) | (134,747.20) | +11,736.9% | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (0.06) | (8,650,615.90) | (8,375,432.53) | (116,779.28) | (539.15) | +8,535.5% | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (44,117.65) | (6,066.07) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (0.06) | (8,650,615.90) | (8,419,550.17) | (122,845.35) | (539.15) | +8,645.5% | ||||||
| Book value | — | — | — | — | — | 0.01 | (0.27) | (511,758.12) | (5,876,297.58) | (53,828.83) | 4,840.05 | n/m | ||||||
| Shares, m | — | — | — | — | — | 3 | 37 | 0 | 0 | 0 | 0 | (91.7%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (2) | (8) | (10) | (16) | (11) | +613.6% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | 0 | +1,484.3% | ||||||
| Free cash flow | — | — | — | — | — | 0 | (2) | (8) | (10) | (16) | (11) | +622.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | (4) | 4 | (8) | (8) | (20) | +212.7% | |||||
| Net debt | — | — | — | — | — | 0 | 1 | (4) | (1) | (2) | (1) | +136.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | 0 | (10) | 0 | (7) | (7) | 103 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (4.13) | (4,481.43) | (14.80) | (311.85) | (796.99) | (55.16) | (792.9) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (21.28) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 97.08 | 10.15 | 491.09 | 561.83 | (69.68) | +561.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | 7 | 6 | 4 | — | +7.5% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
CDT Equity Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JAGX Jaguar Animal Health, Inc. | $950.0K | — (loss-making) | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| SPRC SciSparc Ltd. | $880.0K | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| LNAI Lunai Bioworks Inc. | $830.0K | — (loss-making) | — | — | n/m | −1.65% (below 0%: shrinking) | 100.00% | (6,877.49%) | Compare |
| ATXI Avenue Therapeutics, Inc. | $680.0K | — (loss-making) | — (loss-making) | — | n/m | −169.89% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MLEC Moolec Science SA | $620.0K | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| CDT CDT Equity Inc. | $390.0K | — (loss-making) | — | — | n/m | +78.92% (above 0%: growing) | — | 0.00% | |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR | $320.0K | 0.0× | — (loss-making) | — | −85.80% (below 0%: shrinking) | +51.13% (above 0%: growing) | (228.63%) | (504.50%) | Compare |
| VINC Vincerx Pharma, Inc. | $250.0K | — (loss-making) | — | — | n/m | +42.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| VRPX Virpax Pharmaceuticals, Inc. | $160.0K | — (loss-making) | — | — | n/m | +4.68% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $650.0K | — | — | — | — | +9.26% | 15.84% | (38.96%) |
Pay and ownership Proxy statement filed 11 August 2026
Ownership
Directors and executive officers, together
7.34%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement